BRAND NAMES
 MECHANISM OF ACTION
Cetrorelix is a gonadotropin-releasing hormone antagonist (GnRH antagonist), it blocks the effects of GnRH. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle.
During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization. Cetrorelix blocks such undesirable premature ovulation
Cetrorelix is used in assisted reproduction to inhibit premature premature LH surges in women undergoing controlled ovarian stimulation.
Ovarian stimulation therapy with gonadotropins (FSH, Mentotropins) is started on cycle Day 2 or 3.
Cetrorelix for injection 0.25 mg may be administered subcutaneously once daily starting day 5 or 6 of ovarian stimulation (approximately 96 to 120 hours after start of ovarian stimulation) with urinary or recombinant gonadotrophins and is to be continued throughout the gonadotrophin treatment period including the day of ovulation induction.
When assessment by ultrasound shows a sufficient number of follicles of adequate size, Human chorionic gonadotropin (hCG) is administered to induce ovulation and final maturation of the oocytes.
No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS).
- Hypersensitivity to cetrorelix
- Known hypersensitivity to GnRH or any other GnRH analogs.
- Known or suspected pregnancy, and lactation
 WARNINGS AND PRECAUTIONS
Before starting treatment with Cetrorelix, pregnancy must be excluded
No formal drug interaction studies have been performed with Cetrorelix
 PREGNANCY AND LACTATION
- Pregnancy Category X (US). Cetrorelix is contraindicated in pregnant women.
 SIDE EFFECTS
Adverse Events in ≥ 1%: Ovarian Hyperstimulation Syndrome (3,5%), Nausea (1,3%), Headache (1,1%)